Cargando…

P483 Invasive fungal infection in hematopoietic stem cell transplant recipient from an Indian oncology setting

POSTER SESSION 1, SEPTEMBER 21, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: Invasive fungal infections (IFI) are one of the major causes of morbidity and mortality in post-hematopoietic stem cell transplant (HSCT) recipients. Data from India are limited. The objective was to analyze the incidence, risk...

Descripción completa

Detalles Bibliográficos
Autores principales: Ghafur, Abdul, Das, Bikram, Karthik, Radhika, Easaw, Benjamin M, Raja, Ramanan T, Easaw, Jose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509717/
http://dx.doi.org/10.1093/mmy/myac072.P483
_version_ 1784797288244183040
author Ghafur, Abdul
Das, Bikram
Karthik, Radhika
Easaw, Benjamin M
Raja, Ramanan T
Easaw, Jose
author_facet Ghafur, Abdul
Das, Bikram
Karthik, Radhika
Easaw, Benjamin M
Raja, Ramanan T
Easaw, Jose
author_sort Ghafur, Abdul
collection PubMed
description POSTER SESSION 1, SEPTEMBER 21, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: Invasive fungal infections (IFI) are one of the major causes of morbidity and mortality in post-hematopoietic stem cell transplant (HSCT) recipients. Data from India are limited. The objective was to analyze the incidence, risk factors, and outcomes associated with IFI in our center. METHODS: Adult patients, who underwent marrow/stem cell transplantation between 2014-2018, in an oncology center in India, were included in this retrospective observational study. The revised consensus definition of IFI by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) in 2008, was considered to define cases. Incidence, risk factors, and outcomes associated with IFI were analyzed. RESULTS: Out of the 126 patients who underwent HSCT between 2014-2018, 56 (44.4%) had Allo HSCT, 64 (50.8%) had auto HSCT and 6 (4.8%) had haplo-identical HSCT. A total of 83 (63%) were males and 43 (34%) females, 113 (83.9%) Asians, and 13 (10.3%) Africans. Total 111 (88%) patients received myeloablative conditioning and 24 (19%) received total body irradiation. The hematological conditions were acute myeloid leukemia (AML) n = 23 (18.25%), acute lymphoblastic leukemia (ALL) n = 16 (12.69%), chronic myeloid leukemia (CML) n = 4 (3.17%), Hodgkins lymphoma (HL) n = 17 (13.4%), non-Hodgkins lymphoma (NHL) n = 11 (8.73%), Myeloma n = 35 (27.7%), sickle cell disease n = 13 (10.31%), etc. Most patients received fluconazole 78 (61.9%) followed by micafungin 23 (18.25%), posaconazole 20 (15.87%), voriconazole 4 (3.17%), and liposomal amphoterin B 1 (0.79%) as antifungal prophylaxis. The overall rate of IFI (possible cases included) was auto-HSCT n = 5 (7.81%), and Allo-HSCT n = 5 (8.92%). Among auto-HSCT, the IFI was Proven = 0, Probable n = 1 (1.5%), and Possible n = 4 (6.25%), and among Allo-HSCT Proven = 0, Probable n = 2 (3.57%), and Possible n = 3 (5.35%). These cases had IFI lung based on imaging and serological tests. None of the cases had a lung biopsy. There were no incidents of candidemia. No patients in Haplo-HSCT had IFI. The 1-year survival rate among the IFI cases was 8/10 (80%). As the number of patients with IFI was very low, a meaningful comparison of the risk factors, and the impact of prophylactic regimens were difficult. CONCLUSIONS: The overall rate of IFI in HSCT patients in our setting was low compared to global data.
format Online
Article
Text
id pubmed-9509717
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-95097172022-09-26 P483 Invasive fungal infection in hematopoietic stem cell transplant recipient from an Indian oncology setting Ghafur, Abdul Das, Bikram Karthik, Radhika Easaw, Benjamin M Raja, Ramanan T Easaw, Jose Med Mycol Oral Presentations POSTER SESSION 1, SEPTEMBER 21, 2022, 12:30 PM - 1:30 PM:   OBJECTIVES: Invasive fungal infections (IFI) are one of the major causes of morbidity and mortality in post-hematopoietic stem cell transplant (HSCT) recipients. Data from India are limited. The objective was to analyze the incidence, risk factors, and outcomes associated with IFI in our center. METHODS: Adult patients, who underwent marrow/stem cell transplantation between 2014-2018, in an oncology center in India, were included in this retrospective observational study. The revised consensus definition of IFI by the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) in 2008, was considered to define cases. Incidence, risk factors, and outcomes associated with IFI were analyzed. RESULTS: Out of the 126 patients who underwent HSCT between 2014-2018, 56 (44.4%) had Allo HSCT, 64 (50.8%) had auto HSCT and 6 (4.8%) had haplo-identical HSCT. A total of 83 (63%) were males and 43 (34%) females, 113 (83.9%) Asians, and 13 (10.3%) Africans. Total 111 (88%) patients received myeloablative conditioning and 24 (19%) received total body irradiation. The hematological conditions were acute myeloid leukemia (AML) n = 23 (18.25%), acute lymphoblastic leukemia (ALL) n = 16 (12.69%), chronic myeloid leukemia (CML) n = 4 (3.17%), Hodgkins lymphoma (HL) n = 17 (13.4%), non-Hodgkins lymphoma (NHL) n = 11 (8.73%), Myeloma n = 35 (27.7%), sickle cell disease n = 13 (10.31%), etc. Most patients received fluconazole 78 (61.9%) followed by micafungin 23 (18.25%), posaconazole 20 (15.87%), voriconazole 4 (3.17%), and liposomal amphoterin B 1 (0.79%) as antifungal prophylaxis. The overall rate of IFI (possible cases included) was auto-HSCT n = 5 (7.81%), and Allo-HSCT n = 5 (8.92%). Among auto-HSCT, the IFI was Proven = 0, Probable n = 1 (1.5%), and Possible n = 4 (6.25%), and among Allo-HSCT Proven = 0, Probable n = 2 (3.57%), and Possible n = 3 (5.35%). These cases had IFI lung based on imaging and serological tests. None of the cases had a lung biopsy. There were no incidents of candidemia. No patients in Haplo-HSCT had IFI. The 1-year survival rate among the IFI cases was 8/10 (80%). As the number of patients with IFI was very low, a meaningful comparison of the risk factors, and the impact of prophylactic regimens were difficult. CONCLUSIONS: The overall rate of IFI in HSCT patients in our setting was low compared to global data. Oxford University Press 2022-09-20 /pmc/articles/PMC9509717/ http://dx.doi.org/10.1093/mmy/myac072.P483 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Oral Presentations
Ghafur, Abdul
Das, Bikram
Karthik, Radhika
Easaw, Benjamin M
Raja, Ramanan T
Easaw, Jose
P483 Invasive fungal infection in hematopoietic stem cell transplant recipient from an Indian oncology setting
title P483 Invasive fungal infection in hematopoietic stem cell transplant recipient from an Indian oncology setting
title_full P483 Invasive fungal infection in hematopoietic stem cell transplant recipient from an Indian oncology setting
title_fullStr P483 Invasive fungal infection in hematopoietic stem cell transplant recipient from an Indian oncology setting
title_full_unstemmed P483 Invasive fungal infection in hematopoietic stem cell transplant recipient from an Indian oncology setting
title_short P483 Invasive fungal infection in hematopoietic stem cell transplant recipient from an Indian oncology setting
title_sort p483 invasive fungal infection in hematopoietic stem cell transplant recipient from an indian oncology setting
topic Oral Presentations
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509717/
http://dx.doi.org/10.1093/mmy/myac072.P483
work_keys_str_mv AT ghafurabdul p483invasivefungalinfectioninhematopoieticstemcelltransplantrecipientfromanindianoncologysetting
AT dasbikram p483invasivefungalinfectioninhematopoieticstemcelltransplantrecipientfromanindianoncologysetting
AT karthikradhika p483invasivefungalinfectioninhematopoieticstemcelltransplantrecipientfromanindianoncologysetting
AT easawbenjaminm p483invasivefungalinfectioninhematopoieticstemcelltransplantrecipientfromanindianoncologysetting
AT rajaramanant p483invasivefungalinfectioninhematopoieticstemcelltransplantrecipientfromanindianoncologysetting
AT easawjose p483invasivefungalinfectioninhematopoieticstemcelltransplantrecipientfromanindianoncologysetting